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Summary: 
 
Title:  Increasing the awareness of sepsis 
Name:  Nikola Blajic 
 
Sepsis is a potentially life-threatening systemic inflammatory response in the presence of 
infection, most commonly due to bacterial infection. It occurs predominantly among vulnerable 
patients, such as elderly, immunocompromised or patients with multiple comorbidities.                                                                                       
Pulmonary, gastrointestinal, genitourinary, and primary bloodstream infections account for the 
majority of infectious sources in septic patients. The term „systemic inflammatory response“ 
(SIRS) is used in cases of an evident systemic response in the absence of infection. Severe sepsis 
is sepsis with dysfunction of a least one organ, and septic shock is defined as severe sepsis with 
hypotension. With rising hospitalization rates sepsis clearly became  a problem and has up to this 
time been underestimated by the global health community. A sepsis campaign was founded by 
the non-profit organization Global Sepsis Alliance to increase public and professional awareness 
of sepsis. A higher incidence is particularly due to more resistant bacteria, demographic shifting 
and more surgical procedures amongst others. On the 2nd October 2002 in Barcelona, intensive 
care professionals from around the globe joined to reduce the number of deaths from sepsis. 
Since then unfortunately the Global Burden of Disease Report (GBDR) and the WHO website 
still only list “maternal sepsis” and “sepsis in new-borns”, despite the effort of the surviving 
sepsis campaign. This may partly explain why most non-professionals, journalists and politicians 
do not know the term “sepsis”. Successful early diagnosis and treatment remains difficult and is 
one of the key features of reducing sepsis incidence. In the pathogenesis of sepsis a central 
mediator does not seem to exist, although TNFα has been commonly proposed for this role. 
Diagnosing sepsis includes two or more of these conditions: temperature > 38 ° C or < 36 °, heart 
rate > 90 beats/min, respiratory rate > 20 breaths/min or PaCO2 < 32 torr (< 4.3 kPa), and WBC 
> 12 000 cells/mm3 or < 10% immature forms. Complications of sepsis include end-organ 
dysfunctions also called multiple organ dysfunction syndrome (MODS). The treatment of sepsis 
requires immediate intravenous antibiotics. The initial empiric anti-infective therapy should 
include one or two drugs against all possible pathogens, most commonly gram positive bacteria. 
Keywords: sepsis, increasing awareness, infection, epidemiology, treatment 
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Increasing awareness of sepsis : World Sepsis Day 
 
Apart from the daily hospital environment, lately sepsis came to people’s attention as it was 
reported in the news. In January 2013, a young boy from Queens died because his sepsis was 
detected too late. As a consequence, and being the first politician to introduce this, New York 
Governor Andrew Cuomo announced that hospitals in his state would be required to adopt 
specific guidelines.  
Sepsis occurs when our body exceeds its normal response to an infection by damaging its own 
tissues and organs1,2. It can lead to shock, multiple organ failure, and death, especially if it is not 
recognized early and treated immediately. As early as 1972 Lewis Thomas said that our arsenals 
for fighting off bacteria are so powerful, and involve so many different mechanisms, that we are 
in more danger from them than from the invaders. 
 
The previous failure of new treatments for severe sepsis and septic shock were related to lack 
accurate diagnoses. Physicians, epidemiologists and microbiologists used different definitions 
and terminology for this disease. To capture of valid epidemiological data, it is important to have 
standardized terms. In 1992 sepsis was defined in by the Consensus Conference of the American 
College of Chest Physicians and the Society of Critical Care Medicine (ACCP/SCCM)3 as 
condition in patients with infections that have at least two of four criteria of the so-called 
systemic inflammatory response syndrome (SIRS). If this response is related at least to one organ 
dysfunction it is defined as severe sepsis. The concept of septic shock is limited to patients who 
despite adequate treatment still present with circulatory failure. In 2001 the International Sepsis 
Definitions Conference adjusted the concept of SIRS and defined a broader concept of sepsis, 
and again in 2012 by the SCCM and ESICM. They expanded the list of signs and symptoms of 
sepsis with acronym PIRO. In PIRO4, P stands for the predisposition, indicating pre-existing 
comorbid conditions or chronic conditions which affect the patient’s prognosis. I represents 
insult or infection, which suggest the clinical presence of microorganisms and a high index of 
suspicion. R represents the response to the infectious agent, such as hypotension or hypoxemia 
and including the development of SIRS. The last letter O stands for organ dysfunction ranging 
from acute respiratory distress syndrome (ARDS) to acute kidney failure as well as the failure of 
the coagulation system4. PIRO was introduced as a tool for risk assessment and prognosis, to 
    
 
6 
 
increase inclusion of sepsis in clinical trials, and to improve the outcome of therapeutic 
interventions 3. However, these new definitions for SIRS, sepsis, severe sepsis and septic shock 
differ considerably from the microbiologically oriented definitions for epidemiological purposes 
by the Centres for Disease Control  (CDC) in the USA, Europe and the International 
Classification of Diseases (ICD-10). 
Yet, severe sepsis accounts for 20% of all admissions to intensive care units (ICUs) and is the 
leading cause of death in non-cardiac ICUs 5,6. In the US more than 500 patients die of severe 
sepsis daily 5. Nevertheless sepsis is more common if the patient is very young or very old, has a 
compromised immune system, wounds or injuries or has invasive devices such as intravenous 
catheters or breathing tubes. The World Sepsis Campaign was founded to target the reduction of 
mortality rates of sepsis by increasing its awareness in the public and in healthcare professionals. 
What the campaign is trying to promote are two vital elements that predicate the evolution of this 
problem: first, poverty and severe restrictions on basic healthcare and survival needs and 
secondly endemic diseases that predicate the huge prevalence of the problems of sepsis. The 
campaign is advertising pocket cards for healthcare workers and laypeople which are available 
through their website or social media such as Facebook. They are currently being supported in 
2239 hospitals / healthcare services or departments 7.  
 
Figure	  1:	  World	  Sepsis	  Day	  supporters	  by	  countries	  according	  to	  SSC	  2014	  7	  
The idea for the campaign was based on the previous success of the “Milan Declaration” made at 
a meeting of the European Association for the Study of Obesity, which helped raise awareness of 
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the problems of obesity. A similar success is hoped for Surviving Sepsis, which is a collaborative 
project by three major intensive/critical care organizations: the European Society of Intensive 
Care Medicine (ESICM), the Society of Critical Care Medicine (SCCM), and the International 
Sepsis Forum (ISF).  As previously there weren’t any guidelines for treating sepsis, the campaign 
revealed their initial guidelines in 2004 and an updated version was published in 2008. The 
revised guidelines from 2012 contain two bundles, a resuscitation bundle for the first 3 hours and 
a management bundle for the following 6 hours. Apart from the fact that mortality rates from 
sepsis increase for every hour that antibiotic treatment is delayed (see Figure 2), there is also the 
problem that antibiotics are losing their effectiveness because too many patients who don’t need 
them are getting them, or are being given the wrong ones.  
 
Figure	  2:	  Mortality	  increases	  with	  delay	  in	  antibiotic	  therapy	  according	  to	  Kumar	  et.	  al.	  2006	  8	  
The documented incidence of sepsis worldwide is 1.8 million cases each year, but this number is 
confounded by a low diagnostic rate and difficulties in tracking sepsis in many countries 9. For 
the inpatient care of septicaemia or sepsis in 2008, an estimated $14.6 billion was spent on 
hospitalizations for this condition, and from 1997 through 2008, the inflation-adjusted aggregate 
costs for treating patients hospitalized for this condition increased on average annually by 
11.9%10. Although treatment costs increase, septicaemia and sepsis continue to have fatal 
outcomes. In addition, those who survive severe sepsis are more likely to have long-lasting organ 
    
 
8 
 
damage, cognitive impairment, or physical disability. The main challenge for this campaign is 
the difficulty in diagnosis. Because of lack of training, intensive-care physician often miss the 
diagnosis or diagnose it too late. This is especially problematic, given that early treatment is 
associated with greater success 11. However, the incidence of sepsis is increasing due to medical 
progress, which is associated with an increase of invasive, diagnostic and therapeutic procedures. 
In addition there are more elderly patients with the need for intensive therapy. As people age, the 
effectiveness of their immune system begins to decrease, and it becomes much more difficult to 
fight off infections. Moreover, many elderly patients have chronic conditions, such as diabetes, 
that further impairs their immune systems. 
 
 
Figure	  3	  :	  rates	  of	  hospitalization	  for	  septicaemia	  and	  sepsis,	  by	  sex	  and	  age,	  2008,	  	  According	  to	  :	  CDC/NHCS	  ,	  National	  
Hospital	  Discharge	  survey,	  2008	  7	  
The study by Hall et al. on inpatient care for septicaemia and sepsis demonstrated that 
hospitalization rates for those patients aged 85 and over (271.2 per 10,000 population) were 
about 30 times the rate for those under age 65, and were more than four times higher than the 
rate of 65.7 per 10,000 for the 65–74 age group 10. Furthermore the incidence of sepsis is high in 
premature babies and neonates who have underdeveloped immune systems, making it for them 
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problematic to fight off infections. Infants born before 37 weeks of gestation and those born with 
meconium staining are at high risk for developing sepsis. Mortality for septic infants is up to 
50% 12. Another risk group are obese patients, who are often less ambulatory and are bedridden 
so that they develop bedsores, which are perfect locations for infection development. Major 
trauma and burns also put patients at increased risk for infections by destroying the body's 
natural protective barrier. However, sepsis may occur in an otherwise healthy person and can 
occur very quickly. 
Further reasons for the growing sepsis rates might be immunosuppressive drugs, chemotherapy, 
organ transplantation, and increasing microbial resistance to antibiotics. The European 
Antimicrobial Resistance Surveillance Network (EARS-Net) reports that MRSA remains a 
public health priority as the percentage is still above 25% in seven of the 30 reporting countries 
13. Particularly there are high percentages and increasing trends of antimicrobial resistance in 
gram-negative bacteria in Europe described in this report, which illustrates the continuous loss of 
effective antimicrobial therapy against these microbes and underlines the need for extensive 
strategies targeting all health care sectors. The CDC report from 2013 estimates that in the US 
more than two million people are affected every year with antibiotic-resistant infections, with at 
least 23,000 dying as a result. In fact, we are in an emerging crisis of antibiotic resistance for 
microbial pathogens throughout the world. Antibiotic resistance on epidemic scale has been 
described in numerous pathogens by CDC and EARS.  
The initial goal of the sepsis campaign was to reduce sepsis rates by 25% within 4 years. It took 
them in total approximately 8 years to reduce it by 20 %. This represents 20 % of relative risk 
reduction 14. According to the prospective cohort study on the outcome of the SSC in ICU by 
Levy, M.M., et al., unadjusted hospital mortality rates decreased from 37.0% in the first quarter 
in the campaign to 30.8% by 2 years (P = 0.001).  
    
 
10 
 
 
Figure	  4:	  	  change	  in	  hospital	  mortality	  over	  time	  according	  to	  Levy,	  M.M.,	  et	  al.	  	  14	  
On average, unadjusted mortality rates decreased by 0.91% for each quarter in the campaign 15 
(see Figure 4). So for every quarter that a site or network stays in the campaign, there is about 
1% reduction in hospital mortality from sepsis. In other words, the longer a site stays in the 
campaign, the more patients survive. High compliance sites achieved a RRR up to 36 %15. 
Remick criticises their data saying that sepsis mortality was based on 28-day survival, in contrast 
to most mortality studies, which are based on 5-year survival. Hence, in addition to its high 
lethality, sepsis also contributes to a significant number of years of life lost 16. Improved 
treatment of sepsis could offer decline in global mortality.  
Generally, prevention of sepsis includes increasing awareness in healthcare workers and society, 
reducing antibiotic resistances and better standards of hygiene worldwide, amongst others. 
According to Nelson the prevention from a surgical perspective requires strict adherence to 
aseptic surgical technique, maintaining of a supportive operating room environment, early 
identification and treatment of the high-risk patient, prophylactic antibiotics, and correction of 
any nutritional deficits prior to surgery 17. Hence, better education in triage and treatment 
strategies is needed, including better implementation of the Surviving Sepsis Campaign 
guidelines. Moreover it is important to follow the goal of providing guidance in better antibiotic 
use, aiming to prevent all patient infections by appropriate infection. Kumar et. al. 
retrospectively studied the impact of delay of initiation of appropriate antimicrobial therapy and 
found that it was the strongest predictor in survival 8. If an effective antibiotic was started within 
the first hour of documented hypotension in septic shock, the survival rate was 79.9%. Each 
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further hour of delay over the next 6 hours decreased average survival rates by 7.6%8. 
Noteworthy is however that only 50% of patients received appropriate treatment during the first 
6 hours, which emphasizes the need for antibiotic de-escalation and better guidelines for 
professionals. 
One of the most common places where sepsis is treated is the ICU in our hospitals. The German 
Sepsis Society (Deutsche Sepsis-Gesellschaft e.V. (DSG)) and the German Interdisciplinary 
Association of Intensive Care and Emergency Medicine (Deutsche Interdisziplinäre Vereinigung 
für Intensiv und Notfallmedizin (DIVI)) elaborated on what prevention should include: 
1. Infection prevention models (for ventilator-associated pneumonias, central venous 
catheter- associated bacteremias and urinary catheter-associated urinary tract infections). 
Implementing training programs and universal safety protocols 18 19-26 
2. Manipulation of devises 
2.1 Hygienic hand disinfection 27,28 
2.2 Using aseptic techniques with any central intravascular catheters 29 
2.3 Removal of catheters as soon as they are no longer indicated 30 
2.4 The use of endotracheal tubes with the possibility of subglottal suction can be 
considered as it is associated with decreased risk of pneumonia 31 
3. Keeping the head of the bed elevated whenever possible in intubated patients, to prevent 
ventilator-associated pneumonia (VAP).32 
4. Early oral or parenteral nutrition helps to reduce infections and the duration of inpatient 
stays 33 in surgical patients. 
5. The perioperative or postoperative use of immunomodulating parenteral nutrition 
(arginine, omega-3 fatty acids, nucleotides) is recommended for use in elective surgical 
patients with gastrointestinal tumours or in patients with multiple trauma who are able to 
receive oral nutrition. This nutrition is associated with a reduction of the duration of 
inpatient stay as well as a reduction in the number of nosocomial infection cases.34,35 
6. A moderate intravenous insulin therapy to lower the increased blood glucose levels 
(threshold value of > 150 mg/dl (> 8.3 mmol/l) may be considered in ICU patients. Tight 
glucose control (TGC) revealed no differences in hospital mortality between patients who 
were managed by a ‘tight glycaemic control (TGC)’ protocol and those who were not, i.e. 
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with either an IIT (target values of 80–110 mg/dl) or a moderate glycaemic control 
regimen (target values of <150 mg/dl). 36 
7. Selective bowel decontamination reduced the rate of nosocomial infections in ICU 
patients, especially pneumonia and bacteraemia cases. (For patients with longer 
intubation periods, > 48 h). 37,38 
8. The use of oral antiseptics reduces ventilator associated pneumonias (VAP). 39 
9. When the frequency of infections remains high despite intensive control measures it 
is recommended to use antiseptic-coated catheters. 40,41 
10. It is recommended to administer a pneumococcal, meningococcal and Haemophilus 
Influenzae B vaccine to patients with anatomical or functional asplenism, regardless of 
their underlying disease, prior to or during the inpatient stay after splenectomy. For 
immunosuppressed or chronic patients this recommendation is valid as well.42-45 
 
Prognostic factors for the outcome of sepsis include the host’s response to infection, the site and 
type of microorganism invasion, lactate levels (see Figure 5), and when therapy is commenced. 
 
Figure	  5	  :	  Mortality	  compared	  to	  lactate	  levels	  according	  to	  Trzeciak	  et	  al.	  2007	  46 
 Furthermore a prospective analysis performed in 1992 by Knaus showed that patients with 
sepsis failing to develop fever had a worse outcome 47. New onset atrial fibrillation 48, 
comorbidities such as AIDS or immunosuppression, and advanced age of the patient (above 40) 5 
also have prognostic importance. Age is a risk factor due to increased comorbid conditions and a 
higher exposure to resistant bacteria as stated by Angus et al. 5. Urosepsis showed the lowest 
mortality rate compared to septic shock from ischemic bowel syndrome 49 and nosocomial 
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infections in particular have higher mortality rates compared to community acquired infections 
50,51.  
 
Epidemiology of sepsis:  
 
It is estimated that on average sepsis has an incidence of 56 to 91 cases per 100,000 people, with 
a mortality rate of 30% 52. Nevertheless, these estimates are accompanied by wide margins of 
uncertainty. Hospitalizations for septicaemia or sepsis increased from 326,000 in 2000 to 
727,000 in 2008, and the rate of these hospitalizations more than doubled from 11.6 per 10,000 
people in 2000, to 24 per 10,000 people in 2008 10. The economic burden in Europe for a typical 
episode of sepsis has been estimated to be approximately 25,000 Euros 7. 
Table	  1:	  Identified	  studies	  of	  the	  incidence,	  prevalence	  and	  mortality	  of	  sepsis	  according	  to	  Hall	  et.	  al	  (2011)	  52	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Table 1 shows an overview of identified studies on the incidence, prevalence and mortality from 
sepsis. Unfortunately, there are no respective data yet from developing country. Moreover, 
international and national surveys indicate that 20- 40% of sepsis patients that require treatment 
in the intensive care unit developed their sepsis outside the hospital 53. The rate of sepsis 
developing after surgery trebled from 1997 to 2006 53. 
A study on the outcomes of the Surviving Sepsis Campaign in intensive care units in the USA 
and Europe confirmed a significant difference in their unadjusted mortality. More patients in the 
USA than in Europe were admitted to ICUs from emergency departments and in Europe more 
patients were admitted from general wards 14. In addition the median lengths of stay were slightly 
longer in Europe than in the USA in ICU and in hospital 14. However, patients admitted to the 
ICU with severe sepsis and septic shock in Europe were more severely ill than those in the USA, 
as indicated by increased rates of organ failure, a greater need for mechanical ventilation, and a 
longer length of stay in hospital. The higher unadjusted mortality odds ratio in Europe 
disappeared with severity adjustment 14. This raises the question: are patients being denied early 
ICU access in Europe as compared to the USA, and doing worse as a result? Or are patients 
being unnecessarily over-treated in the US, increasing cost and burden? Concerning this data 
they there is no clear answer but it is probably somewhere in the middle. 
 
Figure	  6:	  Descriptive	  statistics	  by	  region	  according	  to	  Hall	  et.	  al	  (2011)	  14	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Interestingly, the most common source of infection for sepsis was for both countries pneumonia 
(see Figure 6). In the USA the second most common cause was urosepsis whilst in Europe the 
infection site had an abdominal source.   
Also ICU patients are at increased risk for nosocomial infections and have a prevalence of 
nosocomial infections between 5% and 17%54. Additionally there is now a global spread of drug 
resistance among common respiratory pathogens, including streptococcus pneumonia and 
mycobacterium tuberculosis54, and in addition the proportion of coagulase-negative 
staphylococci, methicillin-resistant staphylococcus aureus and enterococci has been rising 
worldwide. Furthermore, the amount of fungal infections has been greatly rising, especially 
caused by candida species, and their mortality rate is over 50% 55. Halting the further spread of 
bacterial resistance will help in reducing sepsis rates, because pneumonia is with 44,6 % the 
most common type of infection for sepsis with a mortality of 36,6%9. The PROGRESS registry 
Promoting Global Research Excellence in Severe Sepsis found out that in Europe after 
pneumonia the most common loci of infection are the abdomen or pelvis in 22.9%, the urinary 
tract in 7.7%, blood in 6.4%, skin 5.0%, other 5.2%, unknown 2.6%, meninges 1.5%, bone and 
joints 1.4%, indwelling catheter or vascular access site 1.4%, and dialysis access site 0.7% 53. 
Nevertheless, 41.4% of patients had gram-negative organisms, 32.4% had gram-positive 
organisms, and in 34%, the infection agent was not determined 53. The location of infection has 
changed during past decades 56 as earlier gram-positive bacteria predominated. Additionally there 
is a difference between ICUs and general wards. In the former, respiratory tract infections are the 
most common, whereas in the latter, urinary tract infections predominate. Mortality is associated 
with the severity of sepsis, the cause of infection and bacterial or fungal aetiology. A Croatian 
study showed that the overall mortality of patients with sepsis in Croatian ICUs was high, but 
outcomes of their treatment were comparable with those in other European countries. The most 
common isolates from positive blood cultures were Escherichia 
coli (11.6%), Pseudomonas species (9,9%), and methicillin-resistant staphylococcus 
aureus (9.3%)57. At the Sisters of Mercy University Hospital in Zagreb (Croatia) an observational 
study showed that sepsis was present in 100 (31.8%), severe sepsis in 89 (28.6%), and septic 
shock in 125 (39.8%) patients with mortality rates 17%, 33.7%, 72.1%, respectively58. Interesting 
is that their data revealed that the most common source of infection was urosepsis, present in 168 
(53.5%) patients, followed by skin or soft tissue infections in 58 (18.5%)58. This differs from the 
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other American and European studies as mentioned above. Nevertheless, early recognition and 
prompt treatment in an appropriate environment as well as competent medical personnel remain 
pivotal. 
 
Pathophysiology of Sepsis:  
 
The pathophysiology of sepsis will be discussed briefly, as it is still not fully understood and a 
detailed description of all the known pathways would go beyond the scope of this thesis. 
The current literature describes 
generally that our defence against 
microbes has been divided into two 
basic types of reactions. First, the 
reactions of innate immunity and 
later reactions of the adaptive 
immunity.  
Both innate and adaptive immunity 
can be seen as two equally important 
parts of our immune system. The innate immune system consists of cells and proteins that are 
always present and ready to mobilize quickly and fight microorganisms at the site of infection. 
However, genetic polymorphisms of toll-like receptor 4 (TLR-4) are associated with a 
predisposition to shock with gram-negative organisms, and mutations in the tumour necrosis 
factor α (TNF-α) receptor affect outcomes from severe sepsis 1. 
The main components of the innate immune system are: physical epithelial barriers, phagocytic 
leukocytes, dendritic cells, natural killer (NK) cell, and circulating plasma proteins59. The 
adaptive immune system is the second line defence system against those pathogens that are able 
to evade or overcome the innate immune defences. Their components adapt to the presence of 
infectious agents by activating, proliferating, and creating efficient mechanisms for neutralizing 
or eliminating the microbes. There are two types of adaptive immune responses: humoral 
immunity, mediated by antibodies produced by B-lymphocytes, and cell-mediated immunity, 
mediated by T-lymphocytes.  
Figure	  7:	  :	  Interaction	  between	  host	  and	  agent	  in	  the	  development	  of	  
sepsis,	  with	  permission	  from	  WIley	  Blackwell1 
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Under normal condition the host response to an infection is initiated when innate immune cells, 
particularly macrophages, recognize and bind to microbial components. Pattern recognition 
receptors (PRRs) on the surface of our immune cells recognize and bind to the pathogen-
associated molecular patterns (PAMPs) of microorganisms. There exist three types of PRRs: toll-
like receptors (TLRs), nucleotide-oligomerisation domain (NOD) leucine-rich repeat proteins, 
and retinoic-acid-inducible gene I (RIG-I)-like helicases59. The binding of host immune cell 
surface receptors to microbes has several effects.                               
 
Figure	  8:	  The	  role	  of	  toll-­‐like-­‐receptors	  (TLRs)	  in	  the	  development	  of	  sepsis,	  ABC	  of	  Sepsis	  (2009)	  with	  permission	  from	  Wiley	  
Blackwell	  1	  
The activation of TLRs produces a signalling cascade via the activation of cytosolic nuclear 
factor-kb (NF-kb). Activated NF-kb moves from the cytoplasm to the nucleus, binds to 
transcription sites, and induces activation of a large set of genes, such as proinflammatory 
cytokines (tumour necrosis factor alpha [TNFα], interleukin-1 [IL-1]), chemokines (intercellular 
adhesion molecule-1 [ICAM-1], vascular cell adhesion molecule-1 [VCAM-1]), and nitric 
oxide59. Furthermore polymorphonuclear leukocytes (PMNs) become activated and express 
adhesion molecules that cause their aggregation and margination to the vascular endothelium. 
The release of mediators by PMNs at the site of infection is mainly the cause for the main signs 
of local inflammation as calor (warmth), rubor (erythema) induced by local vasodilation,  
hyperemia, and protein-rich edema due to increased micro vascular permeability. This process is 
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highly regulated by a mixture of pro-inflammatory and anti-inflammatory mediators secreted by 
macrophages, which have been triggered and activated by the invasion of tissue by bacteria 60,61. 
While the pro-inflammatory environment leads to the recruitment of more PMNs and 
macrophages, the anti-inflammatory mediators inhibit the production of TNFα and IL-11. In 
other words they suppress the immune system by inhibiting cytokine production. The balance of 
pro-inflammatory and anti-inflammatory mediators influences the inflammatory cascade and if it 
is not restored sepsis or SIRS is the result.                                                                                  
During sepsis, the balance is shifted towards cell death and a state of relative 
immunosuppression1. At this late stage, accelerated lymphocyte apoptosis occurs with decreased 
production of pro-inflammatory ensues, which may lead to end-organ failure. Various mediators, 
including tumour necrosis factor-α (TNF-α) and interleukin 1β (IL-1β), induce nitric oxide 
production 14. It causes a decrease in systemic vascular resistance but also causes myocardial 
depression and left ventricular dilatation with decreased ejection fraction1. This leads to an 
elevated cardiac output and generalized vasodilatation, which is described as septic shock. Over 
time myocardial depression becomes more pronounced and may result in a falling cardiac output. 
Capillary leakage occurs with peripheral and pulmonary oedema that may progress to acute lung 
damage and acute respiratory distress syndrome (ARDS). A surge in catecholamines, angiotensin 
II and endothelin causes renal vasoconstriction and increases the risk of renal failure developing.  
In addition to those changes the coagulation cascade shifts towards a pro-thrombotic and anti-
fibrinolytic state mediated by decreased anti-thrombin III, protein C, protein S and tissue factor 
pathway inhibitor levels and prolonged clotting time1. The blood clots when it should not. 
Virchow’s classic triad consists of changes in coagulability, endothelial cell injury, and abnormal 
blood flow. In septic patients, all three of these classic alterations are present and result in 
reduced blood flow to vital organs. Septic patients frequently have poor tissue perfusion in 
addition to inappropriate use of oxygen with resulting cytopathic hypoxia16. Increased thrombin 
levels leads to endothelial and platelet activation. As a result, there is fibrin deposition and 
micro-vascular thrombosis that may insult end organs. The development of disseminated 
intravascular coagulation (DIC) in severe sepsis is a predictor of death and the development of 
multi-organ failure1.  
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Figure	  9:	  Overview	  of	  the	  inflammatory	  response	  during	  sepsis,	  with	  permission	  from	  Nature	  Publishing	  Group	  (2009)	  62	  
In summary, multiple stimuli can cause initiation of different cell types or proteins, as well as the 
complement and coagulation systems. This leads to a higher production of pro-inflammatory 
chemokines and cytokines and up-regulation of adhesion molecules on endothelial and 
polymorphonuclear leukocytes62. Subsequently there is a surge of granular enzymes and 
generations of reactive oxygen species in response to the initial stimulus that occurs in the early 
hyper-reactive phase. As a consequence vascular permeability increases, tissue damage and 
organ failure occur and the innate immune system becomes defective. This leads to the hypo-
reactive phase of the immune response, sometimes resulting in immune paralysis. Finally, in 
Figure 9 shows an overview of the inflammatory response during sepsis. 
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Clinical presentation and diagnosis of sepsis: 
 
Basically the best approach to evaluate any patient admitted to the hospital with a suspicion of 
infection. Unfortunately daily clinical work is not that straightforward, especially with infants. 
Identifying a patient with sepsis remains the cornerstone of success in its therapy. There is no 
typical presentation but most likely the patient presents with fever, tachycardia and tachypnea. 
Table	  2:	  Diagnostic	  criteria	  for	  sepsis	  and	  severe	  sepsis.	  According	  to	  Surviving	  Sepsis	  Campaign	  Guidelines	  (2012)	  63	  
 
Diagnosing sepsis includes two or more of these conditions: temperature > 38 ° C or < 36 °, heart 
rate > 90 beats/min, respiratory rate > 20 breaths/min or PaCO2 < 32 torr (< 4.3 kPa), and WBC 
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> 12 000 cells/mm3 or < 10% immature forms. Table 2 summarizes all diagnostic variables 
according to the current SCC guidelines. 
Some of these criteria need, as already mentioned, should lead to a high index of suspicion. For 
example an altered mental status will always be difficult to identify in older people with 
dementia or with neonates. At the same time this emphasizes how important teamwork between 
nurses and physicians is.  
In order to make diagnosing sepsis as timely as possible, medical professionals can use the 
Modified Early Warning Score (MEWS) and a Screening Tool developed by the British National 
Health Services (NHS). MEWS uses four physiological parameters (systolic blood pressure, 
heart rate, respiratory rate and body temperature) and one observation (level of consciousness, 
AVPU scale) 64, as seen in Table 3. It is an important risk management tool, which not only helps 
to diagnose sepsis or SIRS cases65. With a higher score the parameters should be repeated more 
frequently. A score of higher than 5 indicates that the patient has an increased risk of mortality. 
Table	  3:	  Modified	  Early	  Warning	  Score	  (MEWS),	  AVPU	  =	  Alert,	  Verbal,	  Pain,	  Unresponsive	  -­‐	  adapted	  from	  Lee	  Jr.	  (2014)	  66	  
 
 
The Screening Tool for Sepsis incorporates the MEWS (see Figure 8). Once sepsis is diagnosed 
or suspected, the physician should proceed with the 3 hour and 6 hour treatment guidelines as 
discussed below. 
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Figure	  10:	  Heart	  Of	  England	  Sepsis	  Screening	  Tool,	  according	  to	  ABC	  of	  sepsis	  with	  permission	  from	  Elsevier	  (2009)	  1	  
 
 
 
 
 
 
 
 
    
 
23 
 
Complications of sepsis and scoring systems: 
 
Complications of sepsis include severe sepsis, septic shock and multiple organ dysfunction 
syndrome (MODS), earlier called multiple organ failure (MOF). Severe sepsis is often 
accompanied by respiratory failure, due to diffuse alveolar damage, which can lead to pulmonary 
oedema and failure of oxygenation, also called acute respiratory distress syndrome (ARDS). The 
cardiac output is decreased due to the dilatation of veins and arterioles through the effect of 
nitrous oxide and increased levels of lactate, which acts as a cardiac depressant67 - a vicious 
circle in regard to the hypo-perfusion of our body. Furthermore, renal failure is also seen as 
complication of sepsis and increases the mortality in severe sepsis. The nervous system is 
affected in up to 70% by septic-associated-encelopathy (SAE) and presents as delirium up to and 
including deep coma in severe cases 68. Polyneuropathy has also been found on septic patients, 
which was mostly diagnosed when weaning patients from mechanical ventilation69. In multiple 
organ dysfunction syndrome the body’s homeostasis can not be maintained without intervention. 
MODS is classified into primary and secondary. Primary MODS can be attributed to the direct 
insult itself (eg: renal failure due to rhabdomyolysis), and secondary MODS is organ failure that 
is not in direct response to the insult itself, but is a consequence of the host’s response (eg: acute 
respiratory distress syndrome (ARDS) in patients with pancreatitis) 70.  The over activation of 
intravascular coagulation (DIC) can lead to micro-thrombosis in end-organs, cutaneous 
haemorrhage (purpura fulminans) or even necrosis of peripheral limbs  (see Figure 11). DIC or 
also consumption coagulopathy is often seen in gram-negative sepsis (such as meningococcal 
sepsis). 
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Figure	  11:	  Necrosis	  of	  distal	  fingers	  in	  a	  case	  of	  meningococcal	  sepsis	  with	  permission	  from	  Globalskinatlas.com	  (2014) 
The aetiology of MODS is still not fully understood but generally tissue injury due to infection, 
distributive or haemorrhagic shock, trauma, or inflammation (such as pancreatitis), induces local 
and systemic responses. These responses can lead to a shock, reperfusion injuries, and systemic 
inflammation where organ dysfunction becomes progressive and leads to death. The patient can 
also recover and enter a phase of prolonged rehabilitation. Interestingly the progressive organ 
dysfunction usually follows some kind of predictable course 71. During the first 72 hours of the 
original insult, respiratory failure (acute respiratory distress syndrome, ARDS) commonly occurs 
71,72, which can also remain as interstitial lung fibrosis and be a lifetime restriction for the 
patient’s lung function. In 5 to 7 days hepatic failure ensues and gastrointestinal bleeding occurs 
most likely in the following 10 to 15 days, and finally renal failure in 11 to 17 days 71,72. Even 
though in mild cases the liver seems to be resistant, additionally cholestatic jaundice can occur 70. 
However, there exist a handful of hypotheses as to the mechanisms that initiate and perpetuate 
MODS. In the current literature they talk about so-called “one-hit”, “two-hit” and “sustained 
insult”. Whereas in the one-hit model the initial insult (eg trauma, sepsis) is the cause, in the two-
hit model a subsequent insult (such as catheter induced infection) is the explanation, and in the 
sustained model a continuous insult such as ventilator associated pneumonia is the origin for 
MODS 73. The pathophysiology models such as the “gut hypothesis” is just one of the elaborated 
models, but seems to be amongst most cited ones. Their theory is that due to splanchnic hypo-
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perfusion and endotoxin release the gut mucosal injury increases gut permeability which 
increases translocation of bacteria and their subsequent escape into the systemic circulation to 
activate the host's inflammatory response71,72. In the end, the patient that survives sepsis, has an 
increased risk for developing depression and posttraumatic stress disorder (PTSD). Up to 38% of 
patients after abdominal sepsis reported elevated levels of PTSD symptoms in a study performed 
at the University of Amsterdam 74. 
There are no overall accepted criteria for single organ dysfunction in MODS. However, 
progressive abnormalities of the following organ-specific parameters are commonly used to 
diagnose MODS and scoring systems are used to predict their fatality.  
Table	  4:	  Parameters	  to	  predict	  organ	  dysfunction	  in	  MODS	  adapted	  from	  	  www.uptodate.com	  75	  
PaO2/FiO2 ratio Platelet count Serum bilirubin Serum  
creatinine (or urine output) Glasgow coma score Hypotension 
 
Scoring systems estimate the risk of hospital death based on severity of disease, to help in 
clinical decision making, standardizing research, and comparing the quality of patient care in 
critical care medicine. There exist four different systems: the Acute Physiologic and Chronic 
Health Evaluation (APACHE) system, Simplified Acute Physiologic Score (SAPS), Mortality 
Prediction Model (MPM), and Sequential Organ Failure Assessment score (SOFA). The 
APACHE Score and SOFA are most frequently used. APACHE has different versions from II to 
IV. II and III seem to be the most cited ones. The data is collected during the initial 24 hours of 
ICU admission, taking into account the most critical values. The required data differ among the 
versions, but mostly include factors such as age, diagnosis, prior treatment location, and 
numerous acute physiologic and chronic health variables. The maximum points attainable are 71, 
whereas more than 35 indicate a probable mortality risk of over 80%76. 
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Table	  5:	  Sequential	  Organ	  Failure	  Assement	  (SOFA),	  	  each	  graded	  from	  0	  to	  4	  points	  according	  to	  the	  degree	  of	  dysfunction.	  
Collected 
values 
points +4 +3 +2 +1 0 +1 +2 +3 +4 
Temp. rectal °C ≥ 
41° 
39 - 
40,9° 
 38,5 - 
38,9 
36 - 
38,4° 
34 - 
35,9° 
32 - 
33,9° 
30 - 
31,9° 
≤ 
29,9° 
Mean arterial pressure 
mmHg 
≥ 
160 
130 - 
159 
110 - 
129 
 70 - 
109 
 50 - 69  ≤ 49 
heartrate /min ≥ 
180 
140 - 
179 
110 - 
139 
 70 - 
109 
 55 - 69 40 - 54 ≤ 39 
Respiratory 
frequency /min 
≥ 
50 
35 - 
49 
 25 - 
34 
12 - 24 10 - 
11 
6 - 9  ≤ 5 
Fraction of insprired 
oxygen FiO2 
≥ 
500 
350 - 
499 
200 - 
349 
 < 200 
 |  > 70 
61 - 
70 
 55 - 60 < 55 
pH ≥ 
7,7 
7,6 - 
7,69 
 7,5 - 
7,59 
7,33 - 
7,49 
 7,25 - 
7,32 
7,15 - 
7,24 
< 
7,15 
Na+ ≥ 
180 
160 - 
179 
155 - 
159 
150 - 
154 
130 - 
149 
 120 - 
129 
111 - 
119 
≤ 110 
K+ ≥ 7 6,6 - 
6,69 
 5,5 - 
5,59 
3,5 - 
5,4 
3,0 - 
3,4 
2,5 - 
2,9 
 ≤ 2,5 
creatinine mg/dl ≥ 
3.5 
2,0 - 
3,4 
1,5 - 
1,9 
 0,6 - 
1,4 
 < 0,6   
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haematocrit % ≥ 
60 
 50 - 
59,9 
46 - 
49,9 
30 - 
45,9 
 20 - 
29,9 
 < 20 
leukocyte count (x1000) ≥ 
40 
 20 - 
39,9 
15 - 
19,9 
3 - 14,9  1 - 2,9  < 1 
Glasgow Coma Scale 
(GCS) 
points= 15 - current GCS 
 
The difference between APACHE II and III is, that more variables have been added (such as 
diagnosis or prior treatment location). Crucial is also that the data should be collected on a daily 
basis, which makes APACHE III more accurate.  
 
In contrast, the Sequential Organ Failure Assessment (SOFA) uses simple measurements for 
major organ function to calculate a severity score. The variables are collected 24 hours after 
admission to the ICU and every 48 hours thereafter. The score has 0-24 points, and thereby 
higher scores have a predictability of severe outcome. The mean and highest SOFA scores are 
useful predictors of organ dysfunction. If the initial score during the first 48 hours is elevated 
there is a 50 % risk of mortality 77. In a prospective cohort study by Alan E. Jones the SOFA 
score showed good results in predicting in-hospital mortality when applied to patients with 
severe sepsis with evidence of hypo-perfusion at the time of emergency department admission78. 
Another study showed that SOFA was not any better than APACHE II score in predicting 
outcome79. Nonetheless it is simpler and might therefore be better for everyday use in ICUs. 
On the other hand, a prospective study by Meyer et al. 80 showed that among patients who were 
predicted by clinical assessments and APACHE II scores more likely to die, more than 40% of 
them actually survived. In summary there is no method that is 100% reliable for predicting 
mortality. This shows that a patient’s life should not be evaluated by a statistic; instead it should 
make therapeutic decision easier for physicians in ICUs and should serve as a tool for research 
purposes and comparison. 
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Treatment strategies: 
 
 A standardized approach to any patient with sepsis should include performing Airway, 
Breathing, Circulation, Disability, and Exposure (ABCDE) assessment to initiate immediate 
therapy. The first steps should include airway support, high-flow oxygen, cannulation, fluid 
challenges, urinary output monitoring, blood glucose monitoring and temperature regulation. 
Establishing vascular access and initiating fluid boluses remain crucial when managing patients 
with severe sepsis or septic shock. Afterwards the physician should re-evaluate the high-flow 
oxygen, cannulation, and fluid challenges if the patient is compromised. The 3rd step is to 
perform diagnostics specific to sepsis consisting of blood cultures, lactate measurement, CBC 
with differential and other tests including imaging to identify the source of infection. The last 
step is to start empiric antibiotic therapy and treat the infection, whilst re-evaluating the therapy 
48 hours later.  
Figure 11 shows the 3 hourly and 6 hourly therapeutic goals that need to be reached as adapted 
from the recent Surviving Sepsis campaign guidelines. 
 
Figure	  12:	  Treatment	  guidelines	  adapted	  from	  Surviving	  Sepsis	  Campaign	  2012	  63	  
    
 
29 
 
Early recognition is the cornerstone of initiation for the initiation of sepsis treatment strategies. 
Screening tools as mentioned earlier should be used in order to help the physician start the 
therapy without any delay. It is important to take careful blood cultures samples, as the 
microbiologist can only give you accurate results with properly taken samples. The SSC 
guidelines recommend obtaining at least two sets of blood cultures (aerobic and anaerobic) 
before antimicrobial therapy, with at least one drawn percutaneously and one drawn through 
each vascular access 63. In the case of suspected fungal infection they further suggest the use of 
the 1,3 b-D-glucan assay and mannan and anti-mannan antibody assays, as those assays showed 
positive results earlier than the standard culture methods 81-83, which especially is crucial as 
fungal sepsis has worse outcomes. 
Regarding antibiotic therapy initial empiric therapy should most likely include one or more drugs 
which are effective against all possible pathogens and that penetrate in sufficient concentrations 
into the tissues suspected to be the loci of infection 63. The choice of therapy remains a complex 
issue, in an era of increasing resistance – that is why de-escalation is crucial for success in 
therapy. De-escalation consists of the practice of administering broad-spectrum empirical 
antibiotic therapy together with early re-evaluation and subsequent narrowing down or 
discontinuation of therapy based on clinical improvement and the results of cultures and 
antibacterial susceptibility tests84. 
 
The physician should take into account the patient’s history, including drug allergies and 
intolerances, underlying disease (such as COPD or diabetes), the clinical syndrome, recent 
treatment with antibiotics and the susceptibility patterns of microorganisms in the local hospital 
or area. The British National Health Services developed guidance for antibiotic therapy that I 
summarized in Figure 12. 
Antibiotic therapy usually lasting 7-10 days, except if bone is the source of infection in which 
case treatment lasts usually from 14 days to 4 weeks.  
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Figure	  13	  :	  Antibiotic	  guidance	  therapy	  by	  body	  site,	  tds	  –	  three	  times	  a	  day,	  PO	  –	  per	  os,	  qds	  –	  4	  times	  a	  day,	  bd	  –	  twice	  a	  day,	  
OD	  –	  once	  a	  day,	  MSSA	  –	  methicillin	  sensitive	  staphylococcus	  aureus,	  MRGNB	  –	  multi	  resistant	  gram	  negative	  bacteria 
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The antibiotic therapy needs re-evaluation after 48 hours in order to de-escalate if needed. 
Furthermore the SCC guidelines suggest the use of low procalcitonin levels (or C-reactive 
protein) to help the clinician in the discontinuation of empiric-prescribed antibiotics in patients 
where there is no continuous evidence for infection 63. 
According to the British NHS guidelines the initial therapy for a sepsis of unknown origin should 
be amoxicillin 1g tds IV plus metronidazole 500mg tds IV and gentamicin 5mg/kg IV. 
Nevertheless, in dealing with complex cases the attending doctor should consult the duty 
microbiologist and a senior physician.  
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Conclusion: 
 
In summary, sepsis is a condition that we will be facing more and more in the future. The 
demographic shift of our civilization has led to a higher rate of older people who need more 
medical interventions with a subsequent risk of infection due to numerous comorbidities and 
their age, respectively. Increasing awareness of sepsis is just the first step towards decreasing 
their mortality. Knowing the early signs of sepsis is crucial. The human factor in every hospital, 
community, nursing home, and rehabilitation clinic is important for that awareness. Every hour 
won from sepsis onset to sepsis treatment decreases mortality 15. As long as sepsis is not 
represented in national disease reports, it will be even harder to get it included in the Global 
Burden of Disease Report. To date, the Global Burden of Disease Report (GBDR) and the WHO 
website list only “maternal sepsis” and “sepsis in new-borns”. As sepsis can affect to nearly 
everyone, this is not acceptable. However, it will probably need further clinical trials to achieve 
this.  As stated earlier, those facilities participating in the Surviving Sepsis Campaign reduced 
their mortalities up to 20 % of relative risk reduction. The initial goal of the sepsis campaign was 
to reduce sepsis rates by 25% within 4 years. It took in total approximately 8 years to reduce it 
by 20 % 14. This is an achievement but still needs more support globally. The rising resistance to 
effective antibiotics does not make it any easier to fight sepsis, that is why we need to stress the 
importance of de-escalation therapy in the treatment of any infectious condition.  
In the future sepsis awareness needs to be better outlined for laypeople and professionals – 
starting with the medical student and up to the senior physician. Unfortunately the human race 
likes to procrastinate, as in the meantime the problem becomes bigger.  The answer is probably 
somewhere in the middle and increasing the awareness of sepsis is has definitely needed to be 
addressed for many years. This urges us all to follow the current literature on sepsis, to reach 
beyond the margins of our specialties and follow the published guidelines on topic of sepsis. 
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